Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Conditions
Interventions
MBA-P01 (Botulinum toxin A)
Placebo
Locations
1
South Korea
Chung-And Univ. Hospital
Seoul, Dongjak-gu, South Korea
Start Date
December 28, 2021
Primary Completion Date
June 22, 2022
Completion Date
June 22, 2022
Last Updated
February 24, 2023
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
Medytox Korea
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions